In all, 134 elderly patients (median age 66 years, range 60-75 years) with newly diagnosed acute promyelocytic leukemia (APL) were enrolled in two successive protocols of the Italian multicenter group GIMEMA. All patients received an identical induction with all-trans retinoic acid and idarubicin; 116 (86%) entered complete remission (CR), two (2%) were resistant and 16 (12%) died during induction. After CR, 106 patients received further therapy whereas 10 did not, because of refusal (n ¼ 5) or toxicity (n ¼ 5). Consolidation consisted of three chemotherapy courses in the AIDA protocol (AIDA, 67 patients) or, since 1997, of an amended protocol including only the first cycle (amended AIDA, aAIDA, 39 patients). In the AIDA group, 43 patients (64%) completed consolidation, while seven (11%) and 17 (25%) patients were withdrawn after first and second courses, respectively; nine patients (13%) died in CR and 12 (18%) relapsed. In the aAIDA group, all patients received the assigned treatment; two patients (5%) died in CR and six (15%) relapsed. In the AIDA and aAIDA series, the 3-year overall and discasefree survival rates were 81 and 83% (P ¼ NS), 73 and 72% (P ¼ NS), respectively. We highlight here the frequency and severity of complications linked to intensive chemotherapy in this clinical setting and suggest that, in APL of the elderly, less intensive postremission therapy allows significant reduction of severe treatment-related toxicity and may be equally effective.
Introduction
Acute promyelocytic leukemia (APL) is a well-defined subtype of acute myelogenous leukemia (AML) characterized by peculiar biologic and clinical features including a severe hemorrhagic diathesis at presentation, and a unique response in vitro and in vivo to the differentiating agent all-trans retinoic acid (ATRA). [1] [2] [3] [4] Compared to other AMLs, APL shows a more even age distribution and is less frequently diagnosed in the elderly. 4, 5 The introduction of ATRA and its combination with chemotherapy has led to considerable improvement in the disease outcome by allowing significantly higher complete remission (CR) and disease-free survival (DFS) rates with respect to the pre-ATRA era. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] As to APL in the elderly, to the best of our knowledge only one study specifically focused on this subset has been published to date. 16 This experience, reported by our group, included a small patient series receiving heterogeneous therapies containing ATRA. Results from this study and those pooled out from recent large multicenter ATRA trials including elderly patients, 7, 8, 10, 12, 14 reported high CR rates and prolonged survival, in marked contrast with the extremely poor outcome commonly observed for patients in the same age group affected by other AML forms. 17 However, as compared to younger APL patients, elderly ones had less favorable outcome, mainly because of poor tolerance to intensive chemotherapy rather than to the occurrence of resistant or more aggressive disease. 7, 8, 10, 12, 14 In its multicenter AIDA study, the Italian GIMEMA group reported significantly increased treatment-related toxicity in elderly patients, particularly during post-CR chemotherapy consolidation, that caused frequent withdrawal from study and a sizable fraction of deaths in CR. 7 Based on these observations, the GIMEMA adopted in early 1997 an amended protocol for patients aged X60 years, in which the amount of consolidation was considerably reduced.
In this study, we report the clinical outcome and therapyrelated toxicity observed in elderly APL patients treated according to these successive AIDA-derived protocols. Our data suggest that a less intensive chemotherapy regimen delivered after CR might retain similar antileukemic effects and results in significantly reduced toxicity.
Materials and methods

Diagnostic criteria
APL diagnosis was initially established according to the FrenchAmerican-British (FAB) criteria 18 and confirmed in all patients by molecular identification of the PML/RARa hybrid gene by reverse transcriptase polymerase chain reaction (RT-PCR) and/ or karyotypic detection of the t(15;17) in leukemic cells.
Therapy
Following informed consent, patients received the GIMEMA 0493 protocol 'AIDA', started in 1993 and amended in 1997 for the elderly population in order to reduce the intensity of consolidation: 
Prophylaxis and treatment of ATRA syndrome
Patients received low-dose steroid (6-methylprednisolone 0.3-0.5 mg/kg/day) during induction therapy. Management of ATRA syndrome consisted of prompt discontinuation of ATRA and administration of dexamethasone (10 mg every 12 h for 4 days).
Evaluation of response
Hematological CR was defined as the presence of normal bone marrow (BM) cellularity with the absence of leukemic promyelocytes, with peripheral blood polymorphonuclear and platelet counts 41 Â 10 9 /l and 4100 Â 10 9 /l, respectively. Resistant disease was defined as persistence in the BM of leukemic promyelocytes after 90 days of ATRA treatment. Molecular remission was defined as the absence, on ethidium bromidestained electrophoresis gel, of the specific PML/RARa amplification band detected at diagnosis, in the presence of RNA integrity as evaluated by minigel visualization, and successful amplification of the internal control. 19 RT-PCR analysis of the PML/RARa hybrid gene BM aspirates were obtained at diagnosis, at CR achievement and at the end of consolidation therapy. Following isolation of the BM mononuclear fraction by centrifugation on a FicollHypaque gradient, cells were washed twice in PBS, suspended in a 4 M guanidium thiocyanate solution, stored at À201C and shipped in dry ice to the reference laboratory (University La Sapienza, Rome) for centralized molecular studies. Total RNA was extracted by the method of Chomczynsky and Sacchi. 20 Prior to RT-PCR analysis, the integrity of RNAs was assessed by running samples on a formaldehyde minigel. The protocol and the oligoprimers used for RT-PCR of the PML-RARa hybrid gene are reported elsewhere. 21 Amplification of the PML-RARa hybrid gene was carried out, in all cases, simultaneously with the amplification of a RARa cDNA fragment including exon 2 and exon 3 sequences, in order to further assess RNAa integrity as well as the efficiency of the RT step.
Statistical analysis
Time to event analysis was performed using the Kaplan-Meier method, 22 with differences compared by the log-rank test. 23 Overall survival (OS) was calculated from the date of diagnosis to death from any cause or to the date of last follow-up. DFS was calculated from achievement of CR to relapse and death in CR, or to the date of the last follow-up. Differences in the distribution of individual parameters among patient subsets were analyzed using the w 2 or the Student's t-tests. All statistical comparison used two-tailed P-value. The statistical analysis was carried out using the SAS statistical program (SAS-PC, Version 8.2; SAS Institute Inc., Cary, NC, USA).
Results
Patient characteristics at presentation
Eligibility criteria included demonstration in leukemic cells at diagnosis of the t(15;17) by karyotyping and/or the PML/RARa rearrangement by RT-PCR, no cardiac contraindications to anthracycline chemotherapy and written informed consent. From January 1993 to June 2001, 169 patients aged X60 were registered and 146 were eligible. Of these 146, 134 were evaluable for induction. A total of 48 Italian institutions participated in the studies. The main clinical and biological characteristics of the whole series are shown in Table 1 . Besides a slightly higher incidence of females in elderly APL, no other significant differences were recorded by comparing the main clinical and biological presenting features of this populatioon with those of younger patients (data not shown).
Response to induction treatment
A total of 116 patients (86.6%) obtained hematological CR, two patients (1.5%) showed resistant disease and 16 (11.9%) died during induction. The main clinical features at presentation and the causes of death in these 16 patients are shown in Table 2 . Five patients apparently died of ATRA-derived toxicity, including ATRA syndrome (four cases) and pseudotumor cerebri (one case). Considering the whole group, a 'definitively present' or 'indeterminate' ATRA syndrome, defined as reported elsewhere 7 , was observed in 17 patients (13%). There was no significant association between the development of ATRA syndrome and initial white blood cell (WBC) count.
With respect to prognostic factors influencing CR achievement, age 470 was the most important variable associated with a significantly lower CR rate (P ¼ 0.005). As reported in Table 3 , a significantly lower CR rate was also observed in patients with initial PLTS counts 40 Â 10 9 /l (P ¼ 0.043), whereas neither presenting WBC count nor the PML/RARa junction type significantly influenced the probability of CR achievement.
Postremission outcome
Among 116 patients who achieved CR, 10 did not receive any further treatment because of toxicity (n ¼ 5) or refusal (n ¼ 5). Of the five patients withdrawn for toxicity, three died in CR and two relapsed at 16 and 28 months, respectively. In the group of patients who refused further therapy, three relapsed at 8-21 months and two are alive in CR after 2 and 6 months, respectively. The remaining 106 patients received at least one consolidation cycle. A flow-chart detailing postremission treatment and withdrawals from therapy in the two different protocols AIDA and aAIDA is illustrated in Figure 1. A total of 67 patients were assigned to receive consolidation according to the AIDA protocol. Of these, seven (11%) went offstudy after the first cycle for toxicity, 17 (25%) went off-study after the second cycle (10 for toxicity, six for refusal and one for early relapse), and 43 (64%) patients received the assigned three postremission courses. All 39 patients in the aAIDA group completed the assigned consolidation. Molecular remission was documented in all evaluable cases in both AIDA (59 patients) and aAIDA (35 patients) tested at the end of consolidation, irrespective of the number of cycles received. No significant differences were observed in the main clinical (age, WBC and PLTS counts) and biologic (morphology, PML/RARa isoform) features at presentation of patients receiving the AIDA or aAIDA protocols (not shown).
As to maintenance outcome, the low patient number in the original AIDA did not allow for reliable comparison among the four randomization arms. The vast majority of patients received Figure 1 Flow-chart detailing postremission treatment type with patient number and withdrawals from therapy in the two different protocols AIDA and aAIDA.
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ATRA alone (as recommended in the aAIDA). Toxicity during ATRA maintenance was mild and limited to headache and mucosal/skin dryness (27 and 23% of cases, respectively).
Overall, 23 patients underwent disease relapse and 14 died in CR during different phases of the postremission course (three shortly after induction treatment, eight during consolidation therapy and three after completion of maintenance treatment) ( Table 4 ). In particular, in the AIDA group, nine of 67 patients (13%) died in CR and 12 (18%) relapsed at 3-50 months, while in the aAIDA series two of 39 patients (5%) died in CR and six (15%) relapsed at 7-26 months from CR achievement.
The 6-year OS and DFS of the whole series were 56% (95% CI: 0.44-0.68) and 59% (CI: 0.48-0.70), respectively. The OS curve for the whole series is shown in Figure 2 . The 3-year OS and DFS according to AIDA or aAIDA treatments were 81% (95% CI: 0.71-0.90) and 83% (CI: 0.70-0.96) (P ¼ NS) (Figure 3 ), 73% (CI: 0.61-0.83) and 72% (CI: 0.55-0.89) (P ¼ NS), respectively ( Figure 4) . Finally, there were no statistically significant differences in outcome estimates among patients who had received one, two or three consolidation cycles, irrespective of the assigned treatment.
Discussion
This study confirms that incorporation of ATRA in front-line therapy has markedly improved APL prognosis also in elderly patients, allowing CR and survival rates that are similar to those achieved in younger patients and considerably higher than those of elderly patients with other AML subtypes. Moreover, we highlight here the frequency and severity of complications linked to intensive chemotherapy in this clinical setting and suggest that using a reduced intensity postremission treatment might be appropriate in such patients. With the limits of a nonrandomized groups comparison, outcome results point to a similar antileukemic effect of a single consolidation cycle that, as expected, carried significantly inferior toxicity as compared to the three courses administered in the original AIDA protocol.
Response to induction appeared slightly inferior than that observed in the general APL population treated with the same schedule. 7, 12 In keeping with data of the PETHEMA group who used an identical induction protocol, 12 a significantly lower CR rate was only observed for patients aged 470 years. Combined to both increased toxicity recorded in this group and overall OS for all patients in study (including both postremission protocols AIDA and aAIDA).
Treatment of elderly APL F Mandelli et al rarity of primary resistant cases, this observation suggests that the intensity of induction treatment in patients aged 470 years could be revisited in terms of both ATRA and chemotherapy. Among the observed toxicities, we remark on the higher incidence of cardiac complications and ATRA syndrome in this elderly population as compared to younger patients with APL. 7 As concerns heart toxicity, it is conceivable that this is related to a major susceptibility to anthracycline myocardial toxicity. With respect to ATRA syndrome, the reasons for an increased frequency of this severe complication in the elderly is at present unclear to us and warrants further investigation.
As anticipated in the first report of the multicenter AIDA trial, 7 the three consolidation courses adopted in the original protocol appeared to be poorly tolerated in the elderly. In the present investigation, we report withdrawal from the study during consolidation in approximately 30% of patients because of severe toxicity. Combined to patients that went off-study immediately after CR, this fraction rises to almost 40%, indicating the scarce feasibility of such an intensive and prolonged therapy. Together with long-term outcome comparison in the two AIDA and aAIDA series, our results suggest that schedules combining ATRA and chemotherapy of reduced intensity might be adopted in these patients. This assumption is again strengthened by recent data from the PETHEMA group, using anthracycline-based consolidation omitting nonintercalating drugs, which reported no deaths in CR and all patients in the study to comply with the assigned consolidation, including elderly ones. DFs for patients receiving the standard AIDA or the aAIDA therapy.
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Considering the overall group hereby analyzed, 15/106 (14.1%) patients died in CR from severe toxicity, mainly of infectious nature. It is conceivable to hypothesize that a fraction of these patients might have been cured of their leukemia. Similarly, high rates of death in CR were reported by others and they accounted for as much as 19% of the enrolled elderly patients in the European APL93 study that included two intensive polychemotherapy cycles after remission achievement. 14 A number of recent studies have reported encouraging results in APL using low-dose chemotherapy or even no chemotherapy at all, suggesting that a relevant fraction of patients receiving intensive regimens are currently being overtreated. [25] [26] [27] [28] Apart from the severe toxicity that may be observed in the early phases of therapy, other important emerging problems have been reported recently, such as the occurrence of secondary myelodysplasia/AML. 29 Considering the high chance of prolonged second CR and the possibility to better assess disease status by RT-PCR, all efforts should be made to minimize the life-threatening complications associated with intensive therapy, particularly by identifying at presentation patients with low relapse risk. 24 In this perspective, future strategies might be designed that exploit the use of more targeted approaches including combinations of ATRA, arsenic trioxide, and anti-CD33 monoclonal antibodies.
